

# Influenzavirus B Infections - Pipeline Review, H1 2020

<https://marketpublishers.com/r/I22B6D60908EN.html>

Date: March 2020

Pages: 160

Price: US\$ 2,000.00 (Single User License)

ID: I22B6D60908EN

## Abstracts

Influenzavirus B Infections - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2020, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 10, 5,

2, 18 and 5 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 4, 1 and 1 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Influenzavirus B Infections - Overview

Influenzavirus B Infections - Therapeutics Development

Influenzavirus B Infections - Therapeutics Assessment

Influenzavirus B Infections - Companies Involved in Therapeutics Development

Influenzavirus B Infections - Drug Profiles

Influenzavirus B Infections - Dormant Projects

Influenzavirus B Infections - Discontinued Products

Influenzavirus B Infections - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Influenzavirus B Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Influenzavirus B Infections - Pipeline by AbbVie Inc, H1 2020

Influenzavirus B Infections - Pipeline by Abhelix LLC, H1 2020

Influenzavirus B Infections - Pipeline by Adimmune Corp, H1 2020

Influenzavirus B Infections - Pipeline by Allergy Therapeutics Plc, H1 2020

Influenzavirus B Infections - Pipeline by Ansun Biopharma Inc, H1 2020

Influenzavirus B Infections - Pipeline by Aphios Corp, H1 2020

Influenzavirus B Infections - Pipeline by AstraZeneca Plc, H1 2020

Influenzavirus B Infections - Pipeline by AusBio Ltd, H1 2020

Influenzavirus B Infections - Pipeline by Biotron Ltd, H1 2020

Influenzavirus B Infections - Dormant Projects, H1 2020

Influenzavirus B Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020

Influenzavirus B Infections - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Influenzavirus B Infections, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc  
Abhelix LLC  
Adimmune Corp  
Allergy Therapeutics Plc  
Ansun Biopharma Inc  
Aphios Corp  
AstraZeneca Plc  
AusBio Ltd  
Biotron Ltd  
BlueWillow Biologics Inc  
Cidara Therapeutics Inc  
Cocrystal Pharma Inc  
ContraFect Corp  
e-Therapeutics Plc  
Evotec SE  
Evrys Bio  
Fujifilm Toyama Chemical Co Ltd  
GC Pharma  
Imutex Ltd  
Inovio Pharmaceuticals Inc  
iQur Ltd

Johnson & Johnson  
Medicago Inc  
Novavax Inc  
Osivax SAS  
Park Active Molecules  
Romark Laboratories LC  
Sanofi Pasteur SA  
Sciogen Inc  
Seqirus Ltd  
Serum Institute of India Ltd  
Shanghai Institute of Biological Products Co Ltd  
Shionogi & Co Ltd  
Sinovac Biotech Ltd  
Therapeutic Systems Research Laboratories Inc  
UMN Pharma Inc  
Vacthera BioTech GmbH  
Ventaleon GmbH  
Viramatix Sdn Bhd  
Wuhan Institute of Biological Products Co Ltd

## I would like to order

Product name: Influenzavirus B Infections - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/I22B6D60908EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I22B6D60908EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970